Inventor · disambiguated record
Jean-Christophe Renauld
Also filed as: RENAULD JEAN-CHRISTOPHE
33 granted patents·11 pending applications·519 citations·filing 1990–2020
97Inventor score
Files withLUDWIG INST CANCER RES22LUDWIG INST FOR CANCER RES LTD3RENAULD JEAN-CHRISTOPHE3WYETH CORP3MEDIMMUNE INC2
Top patents by PatentIndex Score
44 records- 0193US10000572B2Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibodyLUDWIG INST FOR CANCER RES LTD·Filed 2014·Granted Jun 19, 2018·22 cites·8 claims
- 0293US6274710B1Antibodies which specifically bind T Cell inducible factors (TIFs)LUDWIG INST CANCER RES·Filed 1998·Granted Aug 14, 2001·94 cites·8 claims
- 0391US5571711AIsolated nucleic acid molecules coding for BAGE tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1993·Granted Nov 5, 1996·69 cites·11 claims
- 0490US6359117B1Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereforLUDWIG INST CANCER RES·Filed 1999·Granted Mar 19, 2002·73 cites·3 claims
- 0589US7972833B2Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereofWYETH LLC·Filed 2007·Granted Jul 5, 2011·10 cites·10 claims
- 0684US7371383B2Recombinant anti-interleukin-9 antibodiesMEDIMMUNE INC·Filed 2003·Granted May 13, 2008·21 cites·44 claims
- 0784US7081528B2Isolated nucleic acid molecules encoding T cell derived inducible factorsLUDWIG INST CANCER RES·Filed 2000·Granted Jul 25, 2006·10 cites·4 claims
- 0884US7033787B2Isolated cytokine receptor LICR-2LUDWIG INST CANCER RES·Filed 2001·Granted Apr 25, 2006·13 cites·15 claims
- 0982US6331613B1Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereofLUDWIG INSTITUE FOR CANCER RES·Filed 1999·Granted Dec 18, 2001·63 cites·22 claims
- 1077US7569667B2Isolated soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereofWYETH CORP·Filed 2006·Granted Aug 4, 2009·1 cites·3 claims
- 1177US7094570B2Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereofLUDWIG INST CANCER RES·Filed 2003·Granted Aug 22, 2006·9 cites·8 claims
- 1277US6645486B1Method of treatment with IL-9 conjugateLUDWIG INST CANCER RES·Filed 2000·Granted Nov 11, 2003·8 cites·11 claims
- 1374US5246701AMethod for inhibiting production of IgE by using IL-9 inhibitorsLUDWIG INST CANCER RES·Filed 1991·Granted Sep 21, 1993·38 cites·8 claims
- 1470US11230603B2Anti-GARP proteinLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Jan 25, 2022·0 cites·15 claims
- 1566US10604579B2Antibody against a complex between human GARP and latent TGF-βLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Mar 31, 2020·0 cites·5 claims
- 1666US7268223B2Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereofWYETH CORP·Filed 2001·Granted Sep 11, 2007·2 cites·2 claims
- 1766US5530096AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jun 25, 1996·22 cites·1 claims
- 1865US5132109AMethod for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereofLUDWIG INST CANCER RES·Filed 1990·Granted Jul 21, 1992·23 cites·2 claims
- 1963US7094396B2Method for making cytokine specific antibodies and uses thereofLUDWIG INSTITIUTE FOR CANCER R·Filed 2003·Granted Aug 22, 2006·1 cites·19 claims
- 2059US2009311802A1Isolated Soluble IL-TIF/IL-22 Receptor or Binding Protein Which Binds to IL-TIF/IL-22 and Uses ThereofRENAULD JEAN-CHRISTOPHE·Filed 2009·Application pending·0 cites
- 2156US2004110189A1Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereofFiled 2003·Application pending·0 cites
- 2256US2003138854A1Method for determining BAGE expressionFiled 2002·Application pending·0 cites
- 2355US2008299134A1Recombinant Anti-Interleukin-9 AntibodiesMEDIMMUNE INC·Filed 2008·Application pending·0 cites
- 2452US7846652B2Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptorWYETH CORP·Filed 2006·Granted Dec 7, 2010·0 cites·6 claims
- 2549US5824551AMethod for modulating cell apoptosisLUDWIG INST CANCER RES·Filed 1995·Granted Oct 20, 1998·18 cites·9 claims
- 2648US2004236075A1Novel glass II cytokine receptors, and uses thereofFiled 2002·Application pending·0 cites
- 2748US2003091533A1Regulation of mononuclear phagocyte stimulationFiled 2002·Application pending·0 cites
- 2847US2003012788A1Method for influencing kinase pathways with IL-22Filed 2002·Application pending·0 cites
- 2944US6465184B1Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereofLUDWIG INST CANCER RES·Filed 1999·Granted Oct 15, 2002·2 cites·7 claims
- 3043US5830454AMethod for treating cell mediated autoimmune disorders using interleukin-9LUDWIG INST CANCER RES·Filed 1996·Granted Nov 3, 1998·6 cites·9 claims
- 3142US2003166150A1Asthma associated factors as targets for treating atopic allergies including asthma and related disordersLUDWIG INST CANCER RES·Filed 2003·Application pending·0 cites
- 3241US5843688AIsolated tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Dec 1, 1998·2 cites·3 claims
- 3340US2005282215A1Isolated cytokine receptor LICR-2RENAULD JEAN-CHRISTOPHE·Filed 2005·Application pending·0 cites
- 3440US2002156013A1Asthma associated factors as targets for treating atopic allergies including asthma and related disordersFiled 2002·Application pending·0 cites
- 3539US6638512B1Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigensLUDWIG INST CANCER RES·Filed 1999·Granted Oct 28, 2003·1 cites·21 claims
- 3639US2003023033A1Novel class II cytokine receptors and uses thereofFiled 2001·Application pending·0 cites
- 3737US5962269AMethods for producing antibodies which specifically bind to interleukin-9 receptorLUDWIG INST CANCER RES·Filed 1995·Granted Oct 5, 1999·3 cites·9 claims
- 3837US5789237ANucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptorLUDWIG INST CANCER RES·Filed 1993·Granted Aug 4, 1998·4 cites·23 claims
- 3936US6110694AMethods for determining complexes of tumor rejection antigens and HLA-Cw*160/moleculesLUDWIG INST CANCER RES·Filed 1998·Granted Aug 29, 2000·2 cites·5 claims
- 4035US6093540AMethod for diagnosing a disorder characterized by expression of a BAGE tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1995·Granted Jul 25, 2000·1 cites·8 claims
- 4132US5877017AIsolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Mar 2, 1999·1 cites·9 claims
- 4230US9234042B2Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion proteinRENAULD JEAN-CHRISTOPHE·Filed 2011·Granted Jan 12, 2016·0 cites·12 claims
- 4324US10138289B2Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion proteinDELPHI GENETICS SA·Filed 2016·Granted Nov 27, 2018·0 cites·8 claims
- 4420US5935929AMethods for treating interstitial lung disease by using interleukin-9 and its antagonistsLUDWIG INST CANCER RES·Filed 1997·Granted Aug 10, 1999·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Jean-Christophe Renauld files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →